NASDAQ:ACIU - AC Immune Stock Price, Forecast & News

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings data on Wednesday, November, 13th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.08. The company earned $33.90 million during the quarter, compared to analyst estimates of $31.50 million. AC Immune had a return on equity of 19.18% and a net margin of 45.19%. View AC Immune's Earnings History.

AC Immune is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for AC Immune.

1 analysts have issued 12 month price targets for AC Immune's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate AC Immune's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 55.1% from the stock's current price. View Analyst Price Targets for AC Immune.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

News coverage about ACIU stock has been trending extremely negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AC Immune earned a news impact score of -4.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for AC Immune.

AC Immune saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 452,700 shares, an increase of 11.4% from the January 15th total of 406,200 shares. Based on an average daily trading volume, of 133,400 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.4% of the shares of the stock are sold short. View AC Immune's Current Options Chain.

Some companies that are related to AC Immune include Epizyme (EPZM), Xencor (XNCR), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), BELLUS Health (BLUSF), Tricida (TCDA), Arvinas (ARVN), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), Aimmune Therapeutics (AIMT), Akcea Therapeutics (AKCA), Zymeworks (ZYME) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Ocular Therapeutix (OCUL), Abeona Therapeutics (ABEO), JD.Com (JD), Sorrento Therapeutics (SRNE), NovaBay Pharmaceuticals (NBY), Arbutus Biopharma (ABUS) and Catalyst Pharmaceuticals (CPRX).

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

AC Immune's stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (16.79%), Renaissance Technologies LLC (0.72%), Acadian Asset Management LLC (0.48%), Marshall Wace LLP (0.20%), FMR LLC (0.10%) and Alpine Woods Capital Investors LLC (0.06%).

ACIU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Geode Capital Management LLC, Marshall Wace North America L.P., Tower Research Capital LLC TRC and ProShare Advisors LLC.

ACIU stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, BVF Inc. IL, Alpine Woods Capital Investors LLC, Oxford Asset Management LLP, Trexquant Investment LP and Spark Investment Management LLC.

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACIU stock can currently be purchased for approximately $7.09.

AC Immune has a market capitalization of $479.01 million and generates $7.36 million in revenue each year. The company earns $-52,090,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AC Immune employs 92 workers across the globe.View Additional Information About AC Immune.

The official website for AC Immune is http://www.acimmune.com/.

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]